Synthesis and applications of 2,4-disubstituted thiazoles derivatives as small molecule modulators of cellular development. by Zhou,  G.-L. et al.
Durham Research Online
Deposited in DRO:
22 May 2014
Version of attached ﬁle:
Accepted Version
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Zhou, G.-L. and Tams, D. M. and Marder, T. B. and Valentine, R. and Whiting, A. and Przyborski, S. A.
(2013) 'Synthesis and applications of 2,4-disubstituted thiazoles derivatives as small molecule modulators of
cellular development.', Organic biomolecular chemistry., 11 (14). pp. 2323-2334.
Further information on publisher's website:
http://dx.doi.org/10.1039/c3ob00005b
Publisher's copyright statement:
Additional information:
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
Journal Name 
Cite this: DOI: 10.1039/c0xx00000x  
www.rsc.org/xxxxxx 
Dynamic Article Links ► 
ARTICLE TYPE 
 
This journal is © The Royal Society of Chemistry [year]  [journal], [year], [vol], 00–00  |  1 
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Understanding how the structure of molecules relates to their function and biological activity is essential 
in the development of new analogues with targeted activity. This is especially relevant in mediating 
developmental processes in mammalian cells and the regulation of stem cell differentiation. In this study, 
thiazole-containing small molecules were synthesised and investigated for their ability to induce the 10 
differentiation of human pluripotent stem cells and their derivatives. Analyses of cell morphology, cell 
viability, expression of cell surface markers and ability to induce cell differentiation and regulate neurite 
formation identified the analogue with the longest and most bulky hydrophobic side chain as possessing 
comparable or enhanced activity to all-trans-retinoic acid (ATRA). Interestingly, a shorter, less bulky, 
known thiazole compound reported to be isoform selective for the retinoic acid receptor β2 (RARβ2) 15 
agonist did not mediate differentiation under the conditions tested, however, activity could be restored by 
adjusting the structure to a longer, more bulky molecule. These data provide further insight into the 
complexity of compound design in terms of developing small molecules with specific biological activities 
to control the development and differentiation of mammalian cells.
Introduction 20 
Retinoids are a class of signalling molecules that include vitamin 
A along with its natural and synthetic analogues. These small 
molecules are involved in regulating important biological 
pathways from embryogenesis through to adult homeostasis, and 
influence the proliferation and differentiation of a diverse range 25 
of cell types, including those of the nervous system.1 All-trans-
retinoic acid (ATRA) in particular is the major metabolite of 
vitamin A; however, due to the presence of five conjugated 
double bonds, it is susceptible to photo-isomerisation into 
different retinoic acid isomers. In cell culture studies such 30 
isomers were found to induce a variety of different cellular 
effects compared to the use of ATRA.2 The propensity for natural 
retinoids to isomerise or be removed by degradation and/or  
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metabolism potentially makes routine handling of these small 
molecules difficult in the laboratory. 
Synthetic retinoids have been utilised with great success in 55 
probing the cellular effects of retinoids while avoiding these 
issues.3 In particular, synthetic retinoid EC23, and its sila-
analogue, contain a triple bond linker region that prevents 
isomerisation and has been shown to be more stable and hence, 
more potent compared with ATRA.4 Indeed, enhanced 60 
differentiation of human pluripotent TERA2.cl.SP12 embryonal 
carcinoma (EC) stem cells and ReNcell 197VM neural progenitor  
cells has been observed during treatment with EC23.4c 
 
ATRA 65 
 
EC23 
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The effects of retinoids are mediated primarily through binding 
to, and activation of, retinoic acid receptors (RARs) and retinoid 
X receptors (RXRs) which are members of the ligand-dependent 
transcription factor superfamily of nuclear receptors.5 Three 
subtypes of RARs exist: α, β and γ; all of which have been 5 
studied extensively in the F9 murine embryonal carcinoma stem 
cell line, and have provided important insights into the different 
roles of each subtype.6 While ATRA and related synthetic 
retinoids such as EC23 are pan-agonists for the RARs and are 
useful general inducers of stem cell differentiation, more 10 
attention is now being focused on the synthesis of subtype-
selective ligands that would facilitate further studies into the 
function of these receptors. However, this is a complicated 
endeavour due to the highly similar nature of the RAR ligand 
binding domains (LBDs): the domain of RARβ differs from that 15 
of RARα and RARγ by one and two residues respectively. 
Nevertheless, small molecules exhibiting subtype-selective 
activities have been discovered via high throughput screening 
assays.7 A 3D comparison of the RAR LBDs found that the 
RARβ binding site was significantly larger due to the presence of 20 
an additional cavity between H5 and H10 caused by the position 
of the I263 side chain.
8 It may be postulated, therefore, that ligands 
with larger side-chains are able to occupy the additional space 
within the RARβ retinoid binding site and hence, may acquire 
selectivity for this subtype. 25 
 
 
Differential promoter usage and alternative splicing produce the 
different isoforms observed with each RAR subtype; the RARβ 
gene has four isoforms: β1-4. RARβ2 is the most abundant 30 
isoform and is of particular interest in the area of neuroscience 
research. In one study, up regulation of RARβ2 was observed in 
both embryonic and adult mouse dorsal root ganglia (DRG) 
neurons exposed to ATRA, along with a corresponding 
stimulation of neurite outgrowth.9 In models of nervous system 35 
injury, overexpression of RARβ2 by lentiviral vectors in adult 
DRG or corticospinal tract neurons resulted in axonal outgrowth 
and functional recovery.10 It would appear, therefore, that RARβ2 
is the crucial transducer of the retinoic acid signal in neurons, and 
ligands selectively targeting this isoform would greatly benefit 40 
studies exploring conditions associated with an absence or lack of 
function of this receptor. However, the design of isoform-
selective agonists represents an even more challenging prospect 
since isoforms of a particular RAR subtype possess identical 
ligand-binding domains, and differences lie entirely within the 45 
ligand independent N-activation domain.11 
Despite these difficulties, agonists for RARβ2 have been 
identified using a high throughput screening assay of a chemical 
library, namely receptor selection and amplification technology 
(R-SAT).12 Alkoxythiazole 1 was reported to be such a 50 
compound, displaying 78% of the activity for RARβ2 compared 
to the reference compound, AM-580. Thus, in order to explore 
any relationship between isoform-selectively and the inducement 
of cellular effects, 1 was synthesised along with two novel 
derivatives containing more bulky phenyl (2) and 1,1,4,4-55 
tetramethyl-1,2,3,4-tetrahydronaphthyl (3) side-chains with the 
aim of performing in vitro assays on cell differentiation and 
neural development to observe any changes in cell growth and 
morphology. 
Results and Discussion 60 
Synthesis of small molecules 
Synthesis of the reported RARβ2-selective agonist 1 was based 
on the literature procedure,12 broadly as outlined in Scheme 1. 
Ethyl 4-cyanobenzoate was heated with equimolar equivalents of 
2-mercaptopropionic acid and pyridine under microwave 65 
conditions to provide the desired hydroxythiazole 5 after 
recrystallisation. However, despite TLC and MS analyses 
indicating the presence of only one product, two species were 
observed by 1H NMR spectroscopy and were found to be 
inseparable. The overlapping ethyl signals and an additional 70 
doublet and quartet peak in the alkyl region of the spectrum were 
deduced to be consistent with the keto-tautomer 5b (Scheme 2), 
the occurrence of which was not reported previously and 
constituted a significant proportion of the mixture (approximately 
15%). 75 
The thiazole moiety is present in naturally occurring molecules 
possessing important antibiotic,13 antitumour14 and 
immunosuppressive15 properties. In particular, 4-hydroxy-1,3-
thiazoles are known as active inhibitors of 5-lipoxygenase16 and 
CDK517 and exist in different tautomeric forms. The enol-form is 80 
favoured in polar solvents and the keto-form in nonpolar 
solvents.18 The lower energy of the aromatic 4-hydroxythiazole 
structure, as well as the presence of an aromatic substituent at the 
2-position, is likely to account for the preferred enol form in this 
case.19 Alkylation of the mixture of 5a and 5b would be  expected  85 
to ‘lock’ the product in the aromatic form; indeed, after reaction 
with 2-bromoethyl ethyl ether to give 6, loss of signals associated 
with the keto-tautomer was observed by 1H NMR analysis of the 
product. Following a basic hydrolysis, alkoxythiazole 1 was 
obtained in 56% yield after recrystallisation. 90 
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Scheme 1Synthesis of alkoxythiazole 1.
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Scheme 2Keto-enol tautomerism of 5a. 
 
In order to enable further functionalisation at the 4-position by 5 
means of cross-coupling reactions, and hence, access different 
analogues with more bulky side-chains and of different overall 
lengths, a triflation reaction was performed with the isolated keto-
enol mixture 5. Procedures for the conversion of 
hydroxythiazoles to triflates are known20 and have been 10 
employed in the derivatisation of these compounds into 
biologically useful agents.21 
Initially, the Comins’ reagent was used as the triflating agent; 
however, after stirring with 5 for 6 hours in tetrahydrofuran, TLC 
analysis showed predominately a mixture of starting materials. 15 
The use of triflic anhydride with pyridine also did not provide the 
desired triflate; however, when pyridine was replaced by 
triethylamine, 7 was obtained in 20% yield after silica gel 
chromatography. The yield was improved by use of a more 
hindered base, diisopropylethylamine (DIPEA), which provided 7 20 
in 81% yield after purification (Eqn. 1). 
Suzuki-Miyaura cross-couplings (Scheme 3) were then  
performed with triflate 7 to provide different small molecules 
with retinoid-like structures. Commercially available 4,4,5,5-
tetramethyl-2-phenyl-[1,3,2]-dioxaborolane 8 was reacted with 25 
 
Equation 1 Synthesis of triflate 7. 
 
 triflate 7, using K3PO4 and 3 mol% Pd(dppf)Cl2 as catalyst in 30 
DMF/H2O at 80 °C. After 18 hours reaction and purification by 
silica gel chromatography, 4-(5-methyl-4-phenyl-thiazol-2-yl)-
benzoic acid ethyl ester 9 was isolated in 69% yield. Subsequent 
base hydrolysis of ester 9 by stirring with 3 equivalents of 
LiOH·H2O in THF proved sluggish and low-yielding, despite the 35 
addition of excess base and applying gentle heating over several 
days. However, a microwave-assisted hydrolysis proved more 
effective, providing the desired acid 2 in 88% yield after 
recrystallisation (Scheme 2). Carboxylic acid 3 was prepared in 
an analogous manner using 4,4,5,5-tetramethyl-2-(5,5,8,8-40 
tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3,2]- 
dioxaborolane 10 in 85% isolated yield. 
 
Effect of thiazole retinoid-like small molecules on the 
differentiation of human pluripotent stem cells 45 
Having prepared alkoxythiazole analogues 1, 2 and 3, they were 
assessed for their ability to induce the differentiation of the 
pluripotent human EC stem cell line, TERA2.cl.SP12. Cells of 
this lineage are proven models of human embryonic 
50 
 
Scheme 3Preparation of thiazole derivatives 2 and 3 via Suzuki-Miyaura cross coupling reactions.
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development22 and have been used to study neural 
differentiation.23 Cultures of TERA2.cl.SP12 cells were 
incubated with compounds 1, 2 and 3, supplemented in the 
culture media to a final concentration of 10 µM for up to 14 days. 
 5 
 
 
Fig. 1   Morphological appearance of TERA2.cl.SP12 human pluripotent 
stem cells exposed to 10 µM of ATRA, 1, 2 and 3 for 7 days. Note the 
similar appearance of cells treated with ATRA and 3, and the high cell 10 
numbers in cultures treated with 2 and 3, indicating cells continuing to 
proliferate rather than committing to differentiation. Scale bar represents 
500 µm. 
 
The effects of the test compounds on stem cell differentiation 15 
were compared with the effect of the natural retinoid ATRA, 
which acted as a positive control. Hence, cultures consisting of 
cells treated with 10 µM ATRA in the culture media were also 
established and incubated alongside each other. Further cultures 
were set up and supplemented with the loading vehicle DMSO to 20 
act as a negative differentiation control. The latter were processed 
for analysis after 3 days. In order to minimise ATRA degradation 
and isomerisation, all culture flasks were handled under reduced 
light conditions. For reproducibility of results, cell cultures for 
each compound were set up in triplicate for each time point and 25 
incubated for over 3, 7 and 14 days. 
After 7 days, it became apparent that cell proliferation in cultures 
exposed to compound 3 had slowed considerably, which is 
consistent with cells committing to differentiate in response to 
ATRA. In contrast, cells treated with compounds 1 and 2 30 
continued to proliferate, and very high cell numbers were 
observed (Fig. 1), which is a clear indication that these molecules 
were unable to induce cell differentiation and arrest cell 
proliferation at the concentration used. The appearance of the 
cells after 14 days followed a similar trend, i.e. cell proliferation 35 
slowed in response to ATRA and compound 3, whereas cultures 
exposed to compounds 1 and 2 became over-confluent due to 
continued cell proliferation. 
After incubating for 7 days in compound-supplemented media, 
cells were prepared for an assay of cell viability by combining 40 
culture media containing any potentially detached or dead cells 
with trypsinised live cells from each experimental condition. The 
resulting cell solution from each flask was centrifuged then re-
suspended in 0.1% BSA solution to enable cell counting. Cells 
from cultures exposed to ATRA, 1, 2 and 3 were diluted in a 45 
staining solution and the proportion of live (intact cytoplasmic 
membranes excluded the dye) to dead (compromised cell 
membranes stained positive for the dye) cells was determined 
using a Viacount assay on a Guava EasyCyte cytometer. The 
number of viable cells, percentage viability, and total cell counts 50 
were then recorded (Fig. 2). 
Continued cell proliferation in cultures treated with compounds 1 
and 2 was reflected in the high cell count and number of viable 
cells, whereas with ATRA and compound 3 these values were 
lower as cells exit the cell cycle and commit to differentiation. 55 
However, cells exposed to compounds 1 and 2 showed lower 
percentage viability than with cultures treated with ATRA and 
compound 3 which is consistent with sub-optimal culture 
conditions due to high cell numbers and over cell proliferation. 
The similarity of cell viability values obtained for the ATRA and 60 
compound 3 treated cultures supports the earlier observation from 
cell morphology that these compounds act in a comparable 
fashion when exposed to this cell line. 
In order to quantify the effects of the thiazole-containing 
compounds on inducing differentiation of the TERA2.cl.SP12 65 
cell line, cells were analysed for expression of known markers for 
stem cell and differentiated cell phenotypes. Cells from each 
experimental condition were incubated with antibodies for the 
stem cell antigens SSEA-3 (globoseries stage specific embryonic 
antigen-3) and TRA-1-60 (a keratin-sulphate-associated 70 
glycoprotein stem surface marker). Following this, incubation 
with a secondary fluorescent antibody allowed the proportion of 
cells expressing the marker to be determined through flow 
cytometry (Fig. 3).  
After 3 days, expression of SSEA-3 and TRA-1-60 in cultures 75 
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Fig. 2  TERA2.cl.SP12 EC stem cells incubated for 7 days in culture 
media supplemented with 10 µM of ATRA, 1, 2 or 3. The number of 
viable cells, percentage viability and total cell counts were determined 5 
using a Viacount assay and represented in graphical format (for 
reproducibility, results are the average of triplicate assays  ± SEM for 
each culture condition, n=3). 
treated with ATRA and compound 3 began to decrease compared 
to the DMSO negative control. This was especially clear for 10 
SSEA-3 where levels decreased by approximately 55% and 42% 
in the ATRA and compound 3 cultures, respectively. These data 
provide a strong indication of TERA2.cl.SP12 stem cells 
committing to differentiate in response to these compounds. 
However, no significant change in expression of these stem cell 15 
markers was observed for cells exposed to compounds 1 and 2, 
suggesting that such cells retain a more stem cell-like phenotype. 
After 7 days, expression  
 
  20 
 
 
 
Fig. 3  TERA2.cl.SP12 EC cells exposed to 10 µM of ATRA, 1, 2 and 3 
for 14 days and analysed for expression of stem cell markers (SSEA-3 25 
and TRA-1-60) and a neural marker (A2B5). Expression of SSEA-3 and 
TRA-1-60 decreased significantly with ATRA and 3, with a 
corresponding increase in A2B5 expression. Conversely, a high level of 
stem cell character was observed for 1 and 2, with minimal A2B5 
expression, indicating that these analogues do not induce differentiation. 30 
After 14 days, spontaneous differentiation of cell cultures exposed to 1 
and 2 may account for the decrease in SSEA-3 and TRA-1-60 levels, 
along with the high expression of A2B5. (For reproducibility, results are 
the average of triplicate assays  ± SEM for each culture condition, n=3) 
Journal Name 
Cite this: DOI: 10.1039/c0xx00000x  
www.rsc.org/xxxxxx 
Dynamic Article Links ► 
ARTICLE TYPE 
 
This journal is © The Royal Society of Chemistry [year]  [journal], [year], [vol], 00–00  |  7 
of SSEA-3 and TRA-1-60 in ATRA and compound 3 treated 
cultures was greatly reduced (Fig. 3), while a significant decrease 
in expression was also observed for 1 (approximately 40% and 
30% reduction in expression of SSEA-3 and TRA-1-60, 
respectively). After 14 days, expression of the stem cell antigens 5 
in the ATRA and compound 3 treated cultures remained minimal; 
however, it was surprising to note at this point the dramatic 
reduction in TRA-1-60 expression for cultures treated with 
compounds 1 and 2, indicating that differentiating cells may be 
present. 10 
Since TERA2.cl.SP12 cells are known to form neurons in 
response to exposure to ATRA,20 expression of the antigen A2B5 
(ganglioseries antigen marking early-stage neural cells), which is 
associated with differentiating neural cell types, was also 
monitored by flow cytometry. As expected, A2B5 expression 15 
increased in response to ATRA over the course of the 
experiment. A very similar pattern of expression was recorded in 
cultures treated with compound 3. This suggests that compound 3 
is capable of inducing differentiation of TERA2.cl.SP12 cells, 
and has a comparable level of activity to ATRA. After 7 days, no 20 
significant increase in antigen expression was observed in 
response to compounds 1 and 2, yet by day 14, an elevated A2B5 
expression was recorded that was similar to the levels observed 
with ATRA and compound 3. It would appear that differentiated 
cell types were present in these cultures; however, further 25 
investigation is required to determine if this was the result of 
spontaneous differentiation in the cultures or sub-optimal growth 
conditions rather than the effects induced by these compounds. 
Nevertheless, given the length of time required before a change in 
cell phenotype was observed, it is unlikely that compounds 1 and 30 
2 behave as true inducers of differentiation.  
 
Effect of a thiazole retinoid-like small molecule on neurite 
outgrowth from differentiated human pluripotent stem cells 
 35 
As the thiazole retinoid-like small molecule, compound 3 was 
shown to induce neural commitment by flow cytometric analysis, 
it was hypothesised that these differentiated stem cells would 
subsequently form neurites. To assess neurite outgrowth a human 
model of neurite formation was used. Suspension aggregates of 40 
the human pluripotent stem cell TERA2.cl.SP12 were 
differentiated with 0.1 µM EC23, ATRA or compound 3 for 21 
days by media supplementation, to induce neural commitment. 
EC23 is a photo stable synthetic retinoid that has been found to 
exhibit a higher level of activity towards the induction of neural 45 
differentiation than ATRA.4,25 After 21 days, neurospheres from 
each treatment group were placed on laminin and poly-D-lysine 
coated substrates to induce neurite formation. Neurospheres were 
maintained for 10 days prior to analysis. 
To visualise and quantify neurite outgrowth from each cell 50 
aggregate, immunocytochemical analysis of the neuronal marker 
β-III-tubulin was performed.  β-III-tubulin staining showed the 
formation of many individual neurites projecting from the central 
neurosphere differentiated either with compound 3 or EC23. 
Quantification of neurite number showed a significant 55 
enhancement of neuritogenesis in stem cells differentiated by 
compound 3 or EC23 compared to ATRA or the undifferentiated 
control (Fig. 4). 
The ability of EC23 or compound 3 to enhance neurite outgrowth 
in this model is likely due to the stability of these compounds. 60 
Increased stability may increase retinoic acid receptor activation 
and the reduction in metabolite formation can result in loss of 
heterogeneous biological effects. While no neurites formed in the 
undifferentiated group, the stem cells stopped proliferating and 
TUJ-1 negative cells migrated from the neurosphere, indicating 65 
that retinoic acid receptor activation is essential and sufficient for 
neural differentiation in this model. 
 
 
Fig. 4 Neurite outgrowth from differentiated TERA2.cl.SP12 EC stem 70 
cells.  Cell aggregates were differentiated with 0.1 µM EC23, ATRA or 3 
for 21 days.  Differentiated aggregates were placed onto a laminin and 
poly-D-lysine substrate for 10 days to allow neurites to form. Neurites 
were stained with the pan-neuronal marker β-III-tubulin (green) and cell 
bodies were stained with DAPI (blue).  Results are triplicate. Error bars ± 75 
SEM  *p<0.05 
 
Effect of an RARβ2 agonist on the differentiation of human 
neuroprogenitor stem cells 
Undif f erentiated ATRA 
3 EC23 
 8  |  Journal Name , [year] , [vol ], 00–00  This journal is © The Royal Society of Chemistry [year] 
 
As reported above, the RARβ2 agonist, compound 1, was found 
to be largely ineffective in its ability to induce the differentiation 
of EC stem cells.  We therefore also assessed its ability to 
modulate the differentiation of the neuroprogenitor cell line, 5 
ReNcell 197VM. Stock cultures of these progenitor cells were 
grown and expanded according to previously described 
methods.24 Once the cells had reached approximately 75% 
confluency, experimental conditions were set up involving the 
withdrawal of growth factors from the culture media and the 10 
incorporation of either compound 1, ATRA or EC23 at a final 
concentration of 1 µM. Undifferentiated (growth media 
supplemented with FGF and EGF) and differentiated (without the 
addition of growth factors) control cultures were also established 
to enable comparison of results. Cultures were maintained for 7 15 
days after which phase contrast micrographs were taken and 
showed that as expected, the undifferentiated control cultures 
continued to proliferate and became over-confluent. In contrast, 
the control differentiation cultures ceased to proliferate and by 
day 7 appeared as zones of proliferative cells surrounded by less 20 
populated areas of neural-type cells. Cells exposed to compound 
1 appeared similar to the control differentiation cultures, while 
cells treated with ATRA or EC23 displayed predominately 
neuronal morphology compared to the control cultures. 
Immunocytochemical staining was then performed to record the 25 
expression of the pan-neuronal marker β-III-tubulin and the 
marker of mature neurons, NF-200 (Fig. 5). Quantification of 
positively stained cells for β-III-tubulin and NF-200 showed that, 
compared to the differentiated control cultures, compound 1 did 
not induce significant neuronal differentiation (Fig. 6). Control 30 
differentiation cultures without retinoid supplementation stained 
for the general neuronal marker β-III-tubulin and showed 
minimal levels of NF-200 expression, which is indicative of an 
immature neuronal phenotype. In contrast, cultures exposed to 
ATRA displayed an approximately 1.5-fold increase in cells 35 
staining positive for β-III-tubulin along with a 3-fold increase in 
those staining positive for NF-200. Cells treated with EC23 
displayed a higher level of neuronal morphology with a 2.25-fold 
and 5-fold increase in β-III-tubulin- and NF-200-positive cells, 
respectively. The increase in expression of both neuronal markers 40 
in response to ATRA and EC23 reflects the formation of more 
mature neurons and is consistent with previous observations.4b 
A likely explanation for the apparent greater potency of EC23 
over ATRA may lie in its superior stability 4 and potential lack of 
metabolism. The result of this is a higher effective concentration 45 
of EC23 during incubation with cells under conditions where 
ATRA would be expected to both degrade and be metabolised. In 
addition, EC23 may provide stronger interactions with retinoid 
receptors than the natural ligands. Although EC23 is a potent 
inducer of neuronal differentiation, the mechanism through which 50 
this synthetic retinoid mediates its intracellular effects remains to 
be fully elucidated. 
 
Conclusions 
The experimental evidence demonstrates clearly that compound 3 55 
is able to induce differentiation of the human TERA2.cl.SP12 
embryonal carcinoma stem cells on a level comparable to that of 
the natural retinoid ATRA. Furthermore, at 0.1 µM, 3 
demonstrates enhanced neural commitment and neurite outgrowth 
over ATRA with levels that are comparable to the potent stable 60 
synthetic retinoid EC23. Further characterisation is required to 
determine whether compound 3 demonstrates specificity for a 
particular retinoic acid receptor subtype, and if this may 
contribute toward the positive results observed.  
The shorter, less bulky, thiazole containing compound 1 has been 65 
previously classified as a RARβ2 agonist. However, this 
molecule showed limited ability to modulate the differentiation of 
either the pluripotent TERA2.cl.SP12 or the neuroprogenitor 
ReNcell 197VM cell lines. Although RARβ2 signalling is 
understood to play a role in neurite outgrowth9,10 it did not have a 70 
positive effect of neuritogenesis like ATRA or EC23 under the 
conditions tested.  It remains possible that activation of RARβ2 is 
a necessary, but not sufficient, factor for neuronal differentiation 
by these types of human cells. 
Overall these results further demonstrate how subtle 75 
modifications to the structure of small molecules, specifically the 
function of the bulky side chain, can have a significant effect on 
their biological activity.  Such information about structure 
activity relationships will advance our ability to design new 
compounds developed for specific biological applications. 80 
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Fig. 5 Effect of supplementation of ReNcell 197VM culture media with 1 µM compound 1, ATRA or EC23 on the induction of neural differentiation as observed by immunocytochemical staining for 
markers for β-III-tubulin (a general neuronal marker protein) and neurofilament protein NF-200 (a 200 KDa protein expressed in mature neurons) compared to undifferentiated (undiff) and differentiated (control 
diff) control cultures. Scale bar represents 100 µm.5 
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Fig. 6 Graphical representation of positive cell counts for the 
neuronal marker β-III-tubulin (A) and the mature neuronal marker NF-
200 (B) in cultures exposed to 1 µM 1, ATRA or EC23 compared to 5 
undifferentiated (undiff) and differentiated (con diff) control cultures. 
Triplicate analyses were performed for reproducibility with data 
representing mean ± SEM, n = 3, * < p=0.05. 
 
Experimental 10 
General experimental 
Reagents were purchased from Sigma-Aldrich, Acros or Alfa-
Aesar and used without further purification unless otherwise 
stated. Solvents were dried before use with appropriate drying 
agents. Where indicated, reagents were combined in an 15 
Innovative Technology Inc. nitrogen-filled (BOC) glovebox. All 
glassware was oven-dried (130 ˚C) prior to use. Microwave 
(MW)-assisted reactions were carried out in an Emrys™ 
Optimizer (Personal Chemistry) in septum-containing, crimp-
capped, sealed vials with automatic wattage adjustment to 20 
maintain the desired temperature for a specified period of time. 
Reactions were monitored in situ by TLC, GC-MS or 1H NMR 
spectroscopy to ensure consumption of starting materials before 
reaction workup. Thin layer chromatography (TLC) was 
performed on Polygram SIL G/UV254 plastic-backed silica gel 25 
plates with visualisation achieved using a UV lamp. Column 
chromatography was performed with Davisil Silica gel, 60 mesh. 
GC-MS was performed using an Agilent Technologies 6890 N 
gas chromatograph equipped with a 5973 inert mass selective 
detector and a 10 m fused silica capillary column (5% cross-30 
linked phenylmethylsilicone) using the following operating 
conditions: injector temperature 250 ˚C, detector temperature 300 
˚C, oven temperature was ramped from 70 ˚C to 280 ˚C at 20 
˚C/min. UHP helium was used as the carrier gas. All NMR 
spectra were recorded on either Bruker Avance-400, Varian 35 
Mercury-400, Varian Inova-500 and Varian VNMRS 700 
spectrometers at the following frequencies: 1H: 200, 400, 500 and 
700 MHz; 13C: 176 MHz; 19F: 658.4 MHz. NMR spectra were 
recorded in CDCl3; tetramethylsilane (TMS) was used as the 
internal standard and spin multiplicities are indicated by the 40 
following symbols: s (singlet), d (doublet), t (triplet), m 
(multiplet). J coupling constants are given in Hz. ES-MS was 
performed by the Durham University departmental service using 
an Acquity TQD (Waters UK Ltd.) mass spectrometer and 
accurate mass measurements were obtained on a Thermo LTQ-45 
FT spectrometer. Elemental analyses were carried out using an 
Exeter Analytical E440 machine. IR spectra were recorded on a 
Perkin Elmer FT-IR spectrometer with an ATR attachment. 
Melting point values were measured on a Sanyo Gallenkamp 
apparatus and are uncorrected. 50 
 
4-(4-Hydroxy-5-methyl-thiazol-2-yl)-benzoic acid ethyl ester 
(5) 
Ethyl 4-cyanobenzoate (1.29 g, 7.4 mmol), 2-mercaptopropionic 
acid (0.64 mL, 7.4 mmol) and pyridine (0.59 mL, 7.4 mmol) were 55 
thoroughly mixed in a MW vial and heated at 150 °C for 75 
minutes (5 x 15 min periods). The resulting yellow solid was 
dissolved in ethyl acetate (60 mL). Undissolved material was 
removed by filtration, and recrystallisation from ethyl acetate 
produced yellow crystals that were washed with acetonitrile to 60 
provide 5 as a yellow crystalline solid (1.50 g, 77%); mp 203-205 
°C; νmax (neat, cm
-1) 2980 (C-H), 1709 (C=O), 1580 (C=C), 1510 
(C=C), 1470 (C=C), 1271 (C-O), 1100 (C-O); [a: δH (400 MHz, 
CDCl3) 8.11 (2H, unsymmet. d, J 8.4 Hz, Ar), 7.88 (2H, 
unsymmet. d, J 8.4 Hz, Ar), 4.40 (2H, q, J 7.2 Hz, CH2), 2.36 65 
(3H, s, CH3), 1.42 (3H, t, J 7.2 Hz, CH3); δC (176 MHz, CDCl3) 
166.0, 159.1, 158.7, 136.5, 131.1, 130.3, 125.4, 105.6, 61.2, 14.3, 
9.4 and b: δH (400 MHz, CDCl3) 8.19-8.13 (4H, m, Ar), 4.41 
(2H, q, J 7.2 Hz, CH2), 4.29 (1H, q, J 7.6 Hz, CH), 1.76 (3H, d, J 
7.6 Hz, CH3), 1.43 (3H, t, J 7.2 Hz, CH3); δC (176 MHz, CDCl3) 70 
193.8, 165.3, 159.1, 135.9, 135.5, 130.0, 128.6, 61.7, 49.4, 18.1, 
14.2]; m/z (ESI) 264 (M + H); λmax (EtOH) 244 nm (ε 4 950 M
-1 
cm-1), 356 (5 000); Anal. calcd. for C13H13NO3S: C, 59.30; H, 
4.98; N, 5.32; found C, 58.99; H, 4.97; N, 5.34.  
 75 
4-[4-(2-Ethoxy-ethoxy)-5-methyl-thiazol-2-yl]-benzoic acid 
ethyl ester (6) 
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Compound 5 (197 mg, 0.75 mmol), 2-bromoethyl ethyl ether 
(255 µL, 2.26 mmol), Cs2CO3 (268 mg, 0.83 mmol), KI (373 mg, 
2.23 mmol) and CH3CN (3.75 mL) were mixed in a MW vial and 
irradiated at 150 °C for 10 min. The filtrate was extracted with 
ethyl acetate (20 mL) and washed with brine (3 x 30 mL). The 5 
organic phase was dried with Na2SO4, filtered and concentrated 
onto Celite. Purification of the residue by flash chromatography 
produced 6 as a viscous yellow oil (193 mg, 77%); νmax (neat, cm
-
1) 2976 (C-H), 1715 (C=O), 1273 (C-O), 1106 (C-O); δH (400 
MHz, CDCl3) 8.05 (2H, unsymmet d, J 8.4 Hz, Ar), 7.89 (2H, 10 
unsymmet d, J 8.4 Hz, Ar), 4.54-4.50 (2H, m, CH2), 4.40 (2H, q, 
J 7.2 Hz, CH2), 3.81-3.77 (2H, m, CH2), 3.61 (2H, q, J 6.8 Hz, 
CH2), 2.33 (3H, s, CH3), 1.41 (3H, t, J 7.2 Hz, CH3), 1.24 (3H, t, 
J 6.8 Hz, CH3); δC (176 MHz, CDCl3) 166.1, 160.1, 157.7, 137.7, 
130.7, 130.1, 125.0, 108.9, 69.8, 69.2, 66.6, 61.1, 15.2, 14.3, 9.4; 15 
m/z (ESI) 336 (M + H); λmax (EtOH) 244 nm (ε 33 880 M
-1 cm-1), 
352 (26 460); HRMS (ESI) calcd. for C17H22NO4S 335.1191 (M 
+ H), found 335.1185. 
 
4-[4-(2-Ethoxy-ethoxy)-5-methyl-thiazol-2-yl]-benzoic acid (1) 20 
Compound 6 (183 mg, 0.55 mmol), LiOH·H2O (68 mg, 1.62 
mmol), H2O (825 µL) and THF (2.75 mL) were mixed in a MW 
vial and irradiated at 150 °C for 8 minutes. The reaction mixture 
was acidified with 1M HCl, extracted with ethyl acetate (3 x 20 
mL) and washed with brine (3 x 60 mL). After drying with 25 
MgSO4 and removal of the solvent in vacuo the crude product 
was obtained and recrystallised from ethyl acetate to give 1 as a 
pale yellow crystalline solid (95 mg, 56%); mp 184-185 °C; νmax 
(neat, cm-1) 2858 (C-H), 2554 (O-H), 1673 (C=O), 1606 (C=C), 
1432 (C=C) 1125 (C-O); δH (500 MHz, CDCl3) 8.11 (2H, 30 
unsymmet d, J 8.5 Hz, Ar), 7.93 (2H, unsymmet d, J 8.5 Hz, Ar), 
4.55-4.51 (2H, m, CH2), 3.82-3.78 (2H, m, CH2), 3.61 (2H, q, J 7 
Hz, CH2), 2.34 (3H, s, CH3), 1.25 (3H, t, J 7 Hz, CH3); δC (176 
MHz, CDCl3)  171.1, 160.5, 157.8, 138.9, 131.1, 129.7, 125.4, 
109.7, 70.2, 69.6, 67.1, 15.6, 9.9; m/z (ESI) 308 (M + H); λmax 35 
(EtOH) 240 nm (ε 2 760 M -1 cm-1), 348 (2 940); Anal. calcd. for 
C15H17NO4S: C, 58.61; H, 5.57; N, 4.56; found C, 58.29; H, 5.43; 
N, 4.19.  
 
4-(5-Methyl-4-trifluoromethanesulfonyloxy-thiazol-2-yl)-40 
benzoic acid ethyl ester (7) 
DIPEA (2.65 mL, 15.2 mmol) was added to a stirred solution of 5 
(2.0 g, 7.60 mmol) in CH2Cl2. The flask was cooled to -78 °C 
after which trifluoromethanesulfonic anhydride (4.4 g, 15.2 
mmol) was carefully added. The reaction was allowed to warm 45 
slowly to RT and was stirred overnight under a nitrogen 
atmosphere. CH2Cl2 and water were added and the product 
extracted with three portions of CH2Cl2. The organic extracts 
were combined and washed three times with water. After drying 
with MgSO4 the solvent was removed in vacuo and the brown 50 
residue purified by flash chromatography to give a yellow oil, Rf 
0.32 (20% EtOAc/hexanes). Recrystallisation from hexane 
produced 7 as an off-white crystalline solid (2.1 g, 70%); mp 48-
50 °C; νmax (neat, cm
-1) 1712 (C=O), 1422 (C=C), 1274 (C=C), 
1221 (C-O), 1134 (C-F), 1093 (C-F), 768 (C-H), 693 (C-H), 602 55 
(C-H); δH (700 MHz, CDCl3) 8.10 (2H, unsymmet. d, J 8 Hz, 
Ar), 7.91 (2H, unsymmet. d, J 8 Hz, Ar), 4.41 (2H, q, J 7 Hz, 
CH2), 2.49 (3H, s, CH3), 1.42 (3H, t, J 7 Hz, CH3); δC (176 MHz, 
CDCl3) 166.1, 161.4, 148.5, 136.4, 132.6, 130.6, 125.9, 122.6, 
61.7, 14.7, 10.4; δF (658.4 MHz, CDCl3) -72.5; m/z (ESI) 263 (M 60 
– CF3SO2), 396 (M + H), 418 (M + Na);  max (EtOH) 312 nm 
(23 100 M -1 cm-1); Anal. calcd. for C14H12F3NO5S2: C, 42.53; H, 
3.06; N, 3.54; found C, 42.50; H, 3.07; N, 3.48. 
 
4-(5-Methyl-4-phenyl-thiazol-2-yl)-benzoic acid ethyl ester (9) 65 
Compound 7 (500 mg, 1.26 mmol), phenylboronic acid pinacol 
ester (284 mg, 1.39 mmol, 1.1 equiv), K3PO4 (537 mg, 2.53 
mmol) and Pd(dppf)Cl2 (28 mg, 0.0383 mmol, 3 mol%) were 
combined in DMF and H2O (10:1) in a Young’s tube under an 
inert nitrogen atmosphere and heated at 80 °C for 18 h. The 70 
mixture was dissolved in diethyl ether and washed twice with 
water. The organic layer was dried with MgSO4 and the solvent 
removed in vacuo to give an orange/brown residue which was 
purified by column chromatography (3→5 % EtOAc/hexanes) to 
give a white solid, Rf 0.28 (10% EtOAc/hexanes). 75 
Recrystallisation from ethanol produced 9 as a white crystalline 
solid (246 mg, 60 %); mp 85-87 °C; νmax (neat, cm
-1) 1706 
(C=O), 1278 (C-O), 1100 (C-O), 860 (C-H), 768 (C-H), 699 (C-
H); δH (700 MHz, CDCl3) 8.10 (2H, unsymmet d, J 8.4 Hz, Ar), 
8.03 (2H, unsymmet. d, J 8.4 Hz, Ar), 7.73 (2H, dd, J 7.7 and 1.4 80 
Hz, Ar), 7.47 (2H, td, J 7.7 and 1.4 Hz, Ar), 7.38 (1H, tt, J 7.7 
and 1.4 Hz, Ar), 4.40 (2H, q, J 7 Hz, CH2), 2.64 (3H, s, CH3), 
1.42 (3H, t, J 7 Hz, CH3); δC (176 MHz, CDCl3) 166.5, 162.6, 
153.0, 137.9, 135.2, 131.5, 130.5, 130.0, 129.0, 128.8, 128.1, 
126.4, 61.5, 14.7, 13.4; m/z (ESI) 324 (M + H), 325 (M + 2H), 85 
670 (2M + Na); max (EtOH) 254 nm (22 400 M
-1 cm-1), 330 (18 
100); Anal. calcd. for C19H17NO2S: C, 70.56; H, 5.30; N, 4.33; 
found C, 70.62; H, 5.32; N, 4.44. 
 
4-[5-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-90 
naphthalen-2-yl)-thiazol-2-yl]-benzoic acid ethyl ester (11) 
Compound 7 (500 mg, 1.26 mmol), 1026 (477 mg, 1.52 mmol, 1.2 
equiv), K3PO4 (537 mg, 2.53 mmol) and Pd(dppf)Cl2 (28 mg, 
0.0383 mmol, 3 mol%) were combined in DMF and H2O (10:1) 
in a Young’s tube under an inert nitrogen atmosphere and heated 95 
at 80 °C for 18 h. The mixture was dissolved in diethyl ether and 
washed twice with water. The organic layer was dried with 
MgSO4 and the solvent removed in vacuo to give a white residue 
which was purified by flash chromatography, Rf 0.33 (8 % 
EtOAc/hexanes). Recrystallisation from ethanol afforded 11 as a 100 
fluffy white crystalline solid (410 mg, 75%); mp 161-162 °C; νmax 
(neat, cm-1) 1707 (C=O), 1270 (C-O), 1102 (C-O), 772 (C-H); δH 
(700 MHz, CDCl3) 8.09 (2H, unsymm d, J 8.4 Hz, Ar), 8.03 (2H, 
unsymm d, J 8.4 Hz, Ar), 7.61 (1H, d, J 1.4 Hz, Ar), 7.49 (1H, 
dd, J = 8.4 and 1.4 Hz, Ar), 7.40 (1H, d, J 8.4 Hz, Ar), 4.40 (2H, 105 
q, J 7 Hz, CH2), 2.63 (3H, s, CH3), 1.75-1.70 (4H, m, 2 x CH2), 
1.42 (3H, t, J 7 Hz, CH3), 1.34 (6H, s, 2 x CH3), 1.32 (6H, s, 2 x 
CH3) ; δC (176 MHz, CDCl3) 166.5, 162.3, 153.5, 145.1, 144.9, 
138.1, 132.3, 131.4, 130.4, 129.4, 127.2, 127.1, 126.4, 126.2, 
61.5, 35.5, 35.4, 34.7, 34.6, 32.3, 32.2, 14.7, 13.3; m/z (ESI) 434 110 
(M + H); max (EtOH) 262 nm ( 27 400 M
-1 cm-1), 335 (17 600); 
Anal. calcd. for C27H31NO2S: C, 74.79; H, 7.21; N, 3.23; found 
C, 74.67; H, 7.22; N, 3.17. 
 
 12  |  Journal  Name, [year] , [vol], 00–00  This journal is © The Royal Society of Chemistry [year] 
4-(5-Methyl-4-phenyl-thiazol-2-yl)-benzoic acid (2) 
Compound 9 (100 mg, 0.31 mmol) and LiOH·H2O (39 mg, 0.93 
mmol) were mixed in THF/H2O (2 mL, 3:1 ratio) in a MW vial 
and irradiated at 160 °C for 15 min after which the reaction 
mixture was acidified with 1 M HCl and ethyl acetate was added. 5 
The organic layer was washed twice with brine and dried with 
MgSO4. After in vacuo solvent removal the residue was 
recrystallised from ethanol to give 2 as a white crystalline solid 
(81 mg, 88%); mp 266-269 °C; νmax (neat, cm
-1) 2847 (O-H), 
1674 (C=O), 1284 (C-O), 858 (C-H), 771 (C-H), 700 (C-H), 681 10 
(C-H); δH (500 MHz, DMSO-d6) 8.09 (4H, s, Ar), 7.80 (2H, dd, J 
8 and 1.5 Hz, Ar), 7.55 (2H, td, J 8 and 1.5 Hz, Ar), 7.46 (1H, tt, 
J 8 and 1.5 Hz, Ar), 2.68 (3H, s, CH3); δC (176 MHz, CDCl3) 
167.7, 162.3, 152.5, 137.5, 135.3, 131.2, 131.2, 129.4, 129.2, 
128.8, 126.8, 13.6; m/z (ESI) 294 (M - H); max (EtOH) 255 nm 15 
(23 000 M -1 cm-1), 329 (19 000); Anal. calcd. for C17H13NO2S: 
C, 69.13; H, 4.44; N, 4.74; found C, 68.79; H, 4.46; N, 4.74. 
 
4-[5-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-thiazol-2-yl]-benzoic acid (3) 20 
Compound 11 (100 mg, 0.23 mmol) and LiOH·H2O (29 mg, 0.69 
mmol) were mixed in THF/H2O (2 mL, 3:1 ratio) in a MW vial 
and irradiated at 160 °C for 15 min after which the reaction 
mixture was acidified with 1 M HCl and ethyl acetate was added. 
The organic layer was washed twice with brine and dried with 25 
MgSO4. After in vacuo solvent removal the residue was washed 
with ethanol to give 3 as a white crystalline solid (80 mg, 85%); 
mp 276-278 °C; νmax (neat, cm
-1) 2929 (O-H), 1681 (C=O), 1279 
(C-O), 773 (C-H); δH (500 MHz, DMSO-d6) 8.12-8.05 (4H, m, 
Ar), 7.66 (1H, d, J 1.5, Ar), 7.52 (1H, dd, J 8.5 and 1.5, Ar), 7.48 30 
(1H, unsymmet. d, J 8.5, Ar), 2.66 (3H, s, CH3), 1.75-1.72 (4H, 
m, 2 x CH2), 1.35 (6H, s, 2 x CH3), 1.33 (6H, s, 2 x CH3); δC (176 
MHz, DMSO-d6) 167.8, 162.1, 153.0, 145.3, 145.0, 137.6, 132.5, 
131.2, 130.6, 127.5, 127.2, 126.8, 126.7, 35.5, 35.5, 35.0, 34.8,  
32.6, 32.5, 31.7, 13.6; m/z (ESI) 404 (M - H); max (EtOH) 261 35 
nm (27 000 M -1 cm-1), 333 (17 000); Anal. calcd. for 
C25H27NO2S: C, 74.04; H, 6.71; N, 3.45; found: C, 73.42; H, 
6.75; N, 3.53.  
Tissue culture 
Stock solutions of ATRA (Sigma), EC23 (Reinnervate), 40 
compounds 1, 2 and 3 were prepared in dimethyl sulfoxide 
(DMSO, Sigma) to concentrations of 10 mM. Aliquots of these 
stock solutions were stored at -80 °C in the dark and thoroughly 
defrosted in a water bath set at 37 °C prior to use. Unless 
otherwise stated all plastic-ware was purchased from Becton, 45 
Dickinson and Company. Phase contrast images of cultures were 
obtained using a light microscope (Nikon Diaphot 300) and 
photomicrographs were captured using digital photograp hy 
(Nikon). 
Human pluripotent TERA2.cl.SP12 embryonal carcinoma stem 50 
cells were cultured in DMEM (Sigma) supplemented with 10% 
FCS (Lonza), 2 mM L-glutamine (Lonza) and 100 active units 
each of penicillin and streptomycin (Lonza). Cells were 
maintained in a humidified atmosphere of 5% CO2 in air at 37 °C 
in a Sanyo CO2 incubator and handled under sterile conditions in 55 
a Class 1 microbiological safety cabinet. Cultures were passaged 
using sterile acid-washed glass beads (VWR) or trypsinised using 
a solution of 0.25% (w/v) trypsin (Life Technologies) and 2 mM 
EDTA in PBS to obtain a single-cell suspension for counting. 96-
well plates were used for cell viability studies and cultures 60 
intended for flow cytometric analyses were set up in T25 flasks. 
Human neural progenitor ReNcell 197VM cells (Millipore) were 
maintained under the laboratory conditions described above. 
Before establishing cell cultures, a 20 µg/mL concentration of 
laminin solution was applied to all plastic-ware, incubated at 37 65 
°C for 6 h and then rinsed once with culture medium. Cells were 
maintained in serum-free conditions with DMEM:F12 (1:1, 
Gibco) supplemented with B27 (Invitrogen), 2 mM L-glutamine, 
gentamycin (Gibco) and 50 mg/mL heparin solution (Sigma). For 
proliferation 10 ng/mL fibroblast growth factor (FGF) and 20 70 
ng/mL epidermal growth factor (EGF) were added to the culture 
media before applying to cells. Cells were trypsinised as 
described above. 
Neurite outgrowth assay 
TERA2.cl.SP12 EC cells were maintained as described above. 75 
Aggregates of TERA2.cl.SP12 EC cells were produced by 
creating a single cell suspension and adding 1.5 x 106 cells per 20 
ml of maintenance media to a 90 mm un-treated Petri dish. The 
cells were left to aggregate overnight and subsequently treated 
with the test compound. Aggregates were cultured for 21 days in 80 
the presence of the test compound to induce neural commitment 
and the production of neurospheres prior to analysis of neurite 
outgrowth. To induce neurite outgrowth a 48 well tissue culture 
plate, the well was coated with a solution of 10 µg/mL laminin 
(Sigma) and poly-D-lysine (Sigma) overnight.  The tissue culture 85 
plastic was washed 3 times with sterile PBS prior to the addition 
of the neurospheres. Neurospheres were added to the permissive 
substrate in the presence of the mitotic inhibitors; 10 µM 5-
fluoro-2-deoxyuridine; 10 µM Uridine and 1 µM cytosine-
arabinoside in TERA2.cl.SP12 maintenance media described 90 
previously and incubated at 37 °C 5% CO2 for 10days. 
Neurospheres where then fixed in 4% PFA and visualised by 
immunocytochemical staining of TUJ-1 antibody. Neurites were 
imaged using the Nikon Diaphot 300 and counted for 
quantification using Image J. 95 
Cell viability assay 
Cells were assessed for viability by combining a single cell 
suspension (achieved by the addition of 1 mL 0.25% 
trypsin/EDTA solution) of live cells with detached dead cells 
contained in the culture medium from each flask. Cell numbers 100 
were determined using a haemocytometer. Cells were required to 
be diluted 1:20 in a staining solution for the Viacount assay and 
added to a 96-well plate. The number of viable cells, percentage 
viabilities and total cell numbers were recorded in triplicate for 
each experimental condition. 105 
 
Flow cytometric analysis of pluripotent TERA2.cl.SP12 EC 
cells 
At each time point (except for the negative control flasks, which 
were processed for analysis after 3 d), cultures were washed with 110 
PBS and treated with trypsin to obtain a single-cell suspension as 
described above. Cells were washed three times with PBS to 
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ensure complete removal of trypsin. After centrifugation of the 
cell mixture and removal of the supernatant, the cell pellet was 
re-suspended in 0.1% bovine serum albumin (BSA) solution and 
counted using a haemocytometer. 200 000 cells/well were added 
to a 96-well plate according to the experimental plan. After 5 
centrifugation of the plate at 1000 rpm for 3 min and removal of 
the supernatant, cells were re-suspended in 50 µl of the 
appropriate primary antibody. Each triplicate set of culture 
conditions (ATRA, compounds 1, 2 and 3, as well as the DMSO-
supplemented flasks [on day 3 only]) was analysed at each time 10 
point for expression of the following three antigens: SSEA-3 
(antibody diluted 1:5 in 0.1% BSA), TRA-1-60 (diluted 1:10) and 
A2B5 (diluted 1:40). These primary monoclonal antibodies were 
used as they recognise specific cell surface antigens associated 
with globoseries glycolipids, glycoproteins and ganglioseries, 15 
displaying highly regulated expression profiles in response to 
differentiation of human EC cells.27 One well containing 
undifferentiated control cells was incubated with the mouse 
myeloma marker anti-P3X as a negative control. The plate was 
incubated on ice for 1 h after which excess unbound antibody was 20 
removed by addition of 100 µl of ice-cold 0.1% BSA, 
centrifugation as above and removal of the supernatant. Two 
further washings were carried out with 180 µl of 0.1% BSA, after 
which cells were re-suspended with the fluorescent secondary 
antibody FITC (fluorescein isothiocyanate-conjugated) goat anti-25 
mouse IgM (ICN Pharmaceuticals, Inc.; Aurora, OH; 
http://www.icnpharm.com) diluted 1:100 in 0.1% BSA. After 
incubating the plate in the dark for 1 h on ice, cells were washed 
three times with 0.1% BSA as described above, and re-suspended 
in 200 µl of 0.1% BSA for analysis.  30 
Cell surface antigen expression on TERA2.cl.SP12 stem cells and 
their compound-induced derivatives was observed by indirect 
immunofluorescence and quantified using a flow cytometer 
(Guava Easycyte). A fluorescence threshold was set such that 
cells fluorescing with a greater intensity than approximately 95% 35 
of the cells incubated with the negative control antibody P3X 
were counted as antigen positive. 
 
Immunocytochemistry with neuroprogenitor ReN197 VM 
cells and human pluripotent TERA2.cl.SP12 EC cells 40 
Cells were fixed in 4% paraformaldehyde (PFA) in PBS (Sigma) 
for 30 min at room temperature (RT) and rinsed with PBS. Cell 
membranes were permeabilised by treatment with 1% Triton-X-
100 (Sigma) in PBS for 10 min at RT. Nonspecific labelling was 
blocked by incubation on a bench-top shaker (Fischer Scientific) 45 
for 1 h at RT with a solution of 1% goat serum (Sigma) 
containing 0.2% Tween-20 (Sigma) in PBS. Primary antibodies 
were diluted in blocking solution and incubated with cells for 1 h 
at RT [β-III tubulin antibody (TUJ1, Covance, diluted 1:600); 
NF-200 antibody (AbCam, diluted 1:200)]. After washing three 50 
times for 15 min with PBS cells were incubated for 1 h in the 
dark with FITC-conjugated (anti-mouse Alexafluor 488, 
Invitrogen, diluted 1:600), Cy3-conjugated (anti-rabbit Cy3, 
JacksonLabs, diluted 1:600) fluorescently -labelled secondary 
antibodies and Hoechst 33342 nuclear staining dye (Molecular 55 
Probes, diluted 1:1000) in blocking solution. Cells were washed 
twice more with PBS and left in the final wash for immediate 
imaging. Fluorescence micrographs, including Hoecsht 3342, 
were acquired using the appropriate filter sets and an adapted 
digital camera (Nikon).   60 
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